Ovarian Cancer

Weekly dose-dense chemotherapy is not superior to standard 3 weekly chemotherapy for patients with epithelial ovarian cancer when it comes to progression-free survival and overall survival, though the regimen is safe and effective.

Bhavana Pothuri, MD, discusses patient-reported outcomes with niraparib in advanced ovarian cancer.

Kala Visvanathan, MD, MBBS, MHS, discusses the rationale for ​evaluating lipophilic statins in epithelial ovarian cancer. 

In our exclusive interview, Thomas Herzog, MD, and Kathleen Moore, MD, reviewed the topline results of the 4 positive PARP inhibitor trials in the frontline maintenance setting and provided perspective on the potential applications of these data to clinical practice.

PARP inhibitors have fundamentally changed our therapeutic algorithms in ovarian cancer, even as their use continues to evolve.

David O'Malley, MD, discusses the adverse effects associated with mirvetuximab soravtansine in ovarian cancer.

In our exclusive interview, Robert L. Coleman, MD, FACOG, FACS and Brian M. Slomovitz, MD, discussed the benefits and limitations of PARP inhibition in all-comers with newly diagnosed advanced ovarian cancer and pivotal PARP inhibitor trials in the frontline setting.

Kathleen Moore, MD, discusses the anticipated impact of the phase 3 MIRASOL trial with mirvetuximab soravtansine in patients with platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with a high folate receptor alpha expression.

Lucy Gilbert, MD, MSc, discusses the rationale for evaluating mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.

The majority of women at a high risk of developing ovarian cancer reported having a favorable attitude toward adopting a two-step risk-reducing early salpingectomy and delayed oophorectomy instead of a risk-reducing salpingo-oophorectomy.

Danja Sarink, PhD, discusses the importance of studying race and ethnicity in epithelial ovarian cancer research.

In an interview with OncLive, Kathleen Moore, MD, discusses the MIRASOL trial and the hope for mirvetuximab soravtansine in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high FRα expression.

Mansoor Raza Mirza, MD,  discusses the safety ​profile of niraparib in combination with bevacizumab in platinum-sensitive recurrent ovarian cancer.

Mansoor Raza Mirza, MD, discusses the clinical implications of the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.

Joyce F. Liu, MD, MPH, discusses the results of cediranib in combination with olaparib in a phase 3 trial in patients with recurrent platinum-sensitive ovarian cancer.

Ursula A. Matulonis, MD, discusses the potential role of combined positive score as a biomarker in advanced recurrent ovarian cancer.

In our exclusive interview, Bradley J. Monk, MD, FACS, FACOG, and Maurie Markman, MD, discuss the rationale behind maintenance therapy, pivotal PARP inhibitor trials in the frontline setting, and the importance of shared-decision making.

Mansoor Raza Mirza, MD, discusses the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.

Mansoor Raza Mirza, MD, discusses the evolving treatment landscape in recurrent ovarian cancer.

Kathleen Moore, MD, discusses the current prevalence of ovarian cancer.

Konstantin Zakashansky, MD, discusses data with olaparib in advanced, recurrent, platinum-sensitive, BRCA-mutated ovarian cancer.

The pivotal phase 3 ATHENA trial, which will examine the safety and efficacy of rucaparib in combination with nivolumab as maintenance treatment following response to front-line platinum-based chemotherapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, has completed target enrollment.

Rebecca C. Arend, MD, discusses the unmet needs in of patients with platinum-resistant ovarian cancer.

David O'Malley, MD, discusses the activity of ​the investigational antibody-drug conjugate mirvetuximab soravtansine in ovarian cancer.